<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anthelminthic therapies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anthelminthic therapies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anthelminthic therapies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter F Weller, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karin Leder, MBBS, FRACP, PhD, MPH, DTMH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 21, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Helminths are multicellular parasites with complex life cycles within and outside of human hosts. The mechanisms of action for many anthelminthic agents remain incompletely understood.
        </p>
        <p>
         Anthelminthic drugs are used for treatment of symptomatic disease and for mass drug treatment programs in regions with high prevalence of infection and disease [
         <a href="#rid1">
          1-3
         </a>
         ]. In some endemic areas, deworming strategies have been associated with health benefits including improvements in hemoglobin levels, growth and physical fitness, cognitive performance, and nutritional status [
         <a href="#rid4">
          4-6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/91857.html" rel="external">
          "Mass drug administration for control of parasitic infections"
         </a>
         .)
        </p>
        <p>
         In the United States, some agents are available through the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fncezid%2Fdsr%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLL5728He%2FvLdtW8%2FxFATkgal4zg3beQEfCZcaI9sLBQG&amp;TOPIC_ID=487" target="_blank">
          Centers for Disease Control and Prevention Drug Service
         </a>
         (telephone 1-404-639-3670).
        </p>
        <p>
         An overview of anthelminthic therapies will be presented here. Therapeutic and more detailed considerations for specific helminth infections are discussed separately. (See related topics.)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          IVERMECTIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         is a semisynthetic derivative of avermectin, which is derived from the soil mold
         <em>
          Streptomyces avermitilis
         </em>
         . Ivermectin opens glutamate-sensitive chloride channel currents in helminths and this may be its mechanism of action [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         is lipophilic. In individuals with higher body mass index, this can result in lower plasma levels; however, this can also result in a longer half-life and time to clearance [
         <a href="#rid8">
          8-10
         </a>
         ]. The clinical impact of these effects on treatment efficacy is unknown; given the lipophilicity, we favor dosing based on actual body weight.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         is the drug of choice for the treatment of onchocerciasis and for strongyloidiasis. (See
         <a class="medical medical_review" href="/z/d/html/5683.html" rel="external">
          "Onchocerciasis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">
          "Strongyloidiasis"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         has activity against other filarial worms including
         <em>
          Wuchereria bancrofti
         </em>
         ,
         <em>
          Brugia malayi
         </em>
         , and
         <em>
          Loa loa
         </em>
         . It is not the drug of choice for these infections, though it may be useful in certain circumstances. (See related topics.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         is effective against several intestinal nematodes including ascariasis, trichuriasis, and enterobiasis [
         <a href="#rid11">
          11
         </a>
         ]. Ivermectin is also used to treat cutaneous larva migrans and
         <em>
          Mansonella ozzardi
         </em>
         . Ivermectin is ineffective against human hookworms [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">
          "Ascariasis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5692.html" rel="external">
          "Enterobiasis (pinworm) and trichuriasis (whipworm)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5718.html" rel="external">
          "Hookworm-related cutaneous larva migrans"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83819.html" rel="external">
          "Mansonella infections"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         is also effective for treatment of ectoparasitic infections including scabies and head lice. (See
         <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">
          "Scabies: Epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4035.html" rel="external">
          "Pediculosis capitis"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         should not be administered to pregnant or lactating women, and its safety in children &lt;15 kg is not known. In areas of West Africa where loiasis is endemic, ivermectin should be used with caution; it should be avoided in those with high-grade microfilaremia who are susceptible to treatment-induced encephalopathy. (See
         <a class="medical medical_review" href="/z/d/html/5684.html" rel="external">
          "Loiasis (Loa loa infection)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          BENZIMIDAZOLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benzimidazole class of antiparasitic agents includes four drugs: thiabendazole,
         <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">
          mebendazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          albendazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">
          triclabendazole
         </a>
         .
        </p>
        <p>
         Benzimidazoles exert their anthelminthic effect by binding to free beta-tubulin and thus inhibiting the polymerization of tubulin and microtubule-dependent glucose uptake [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Benzimidazoles should be avoided in pregnant women when possible. When used in mass drug treatment programs for soil-transmitted helminths, the World Health Organization indicates that
         <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">
          mebendazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          albendazole
         </a>
         may be administered to pregnant women in the second and third trimesters [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Albendazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          Albendazole
         </a>
         has a broad range of activity against helminthic infections, including neurocysticercosis, echinococcosis, ascariasis, hookworm, and trichuriasis. (See related topics.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          Albendazole
         </a>
         also has activity against a number of less common tissue nematode infections, including cutaneous larva migrans [
         <a href="#rid13">
          13
         </a>
         ], visceral and ocular larva migrans [
         <a href="#rid14">
          14
         </a>
         ], gnathostomiasis [
         <a href="#rid15">
          15
         </a>
         ], intestinal capillariasis [
         <a href="#rid16">
          16
         </a>
         ], clonorchiasis [
         <a href="#rid17">
          17
         </a>
         ],
         <em>
          Lagochilascaris minor
         </em>
         [
         <a href="#rid18">
          18
         </a>
         ], and human infections with the nematodes
         <em>
          Trichinella pseudospiralis
         </em>
         [
         <a href="#rid19">
          19
         </a>
         ] and
         <em>
          Oesophagostomum bifurcum
         </em>
         [
         <a href="#rid20">
          20
         </a>
         ]. (See related topics.)
        </p>
        <p>
         Absorption of
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          albendazole
         </a>
         is enhanced by taking it with fatty meals [
         <a href="#rid21">
          21
         </a>
         ]. Albendazole should be taken with fatty foods for treatment of invasive systemic parasitic infections; it should be taken with no food (eg, on an empty stomach) for treatment of intraluminal parasitic infections with no systemic involvement. Side effects of albendazole include abdominal pain, nausea, vomiting, and increased hepatic transaminases; these are generally transient and usually do not require discontinuation of the drug [
         <a href="#rid22">
          22
         </a>
         ]. Neutropenia and, rarely, agranulocytosis can occur with longer-term treatments (as for echinococcosis or neurocysticercosis), so blood counts should be monitored. Alopecia can occur during prolonged treatments but resolves after albendazole treatment ends.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Mebendazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">
          Mebendazole
         </a>
         is a benzimidazole derivative that is effective against a spectrum of intestinal and tissue nematode infections, including ascariasis, hookworm, enterobiasis, and trichuriasis, and as an investigational drug for
         <em>
          Capillaria
         </em>
         . Side effects of mebendazole include mild abdominal pain and diarrhea.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Triclabendazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">
          Triclabendazole
         </a>
         is the drug of choice for treatment of liver fluke infections due to
         <em>
          Fasciola hepatica
         </em>
         [
         <a href="#rid23">
          23,24
         </a>
         ]. Triclabendazole should be taken with food to enhance absorption [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5676.html" rel="external">
          "Liver flukes: Fascioliasis"
         </a>
         .)
        </p>
        <p>
         In the United States,
         <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">
          triclabendazole
         </a>
         was approved by the US Food and Drug Administration in February 2019 for treatment of patients with fascioliasis ≥6 years of age [
         <a href="#rid26">
          26
         </a>
         ]. Triclabendazole prolongs the QTc interval but otherwise is generally well tolerated.
        </p>
        <p class="headingAnchor" id="H21576281">
         <span class="h2">
          Thiabendazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thiabendazole is an older benzimidazole derivative that is active against a variety of nematode parasites, but frequent and severe side effects have limited its use [
         <a href="#rid27">
          27
         </a>
         ]. Adverse reactions include dizziness, nausea, vomiting, drowsiness, pruritus, headache, neuropsychiatric disturbances, hepatitis, and hypersensitivity reactions including Stevens-Johnson syndrome. A topical suspension of thiabendazole has been used for cutaneous larva migrans.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          PRAZIQUANTEL
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         has activity against schistosomiasis, intestinal tapeworms, cysticercosis, and other flukes (exclusive of
         <em>
          Fasciola hepatica
         </em>
         ). (See related topics.)
        </p>
        <p>
         Its mechanism of action is unknown, but, in schistosomes, it causes paralysis and tegumental disruption. Side effects include headache, dizziness, drowsiness, nausea, and abdominal discomfort.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          OTHER AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other drugs are available for the treatment of specific helminthic infections.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Diethylcarbamazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="112050" href="/z/d/drug information/112050.html" rel="external">
          Diethylcarbamazine
         </a>
         (DEC) is a piperazine derivative that has activity against lymphatic filariasis, loiasis, and visceral larva migrans. The mechanism of action is uncertain.
        </p>
        <p>
         Side effects in filarial infections are generally proportional to the microfilarial burden and largely attributable to release of lipopolysaccharides and other constituents from endosymbiont
         <em>
          Wolbachia
         </em>
         [
         <a href="#rid28">
          28,29
         </a>
         ]. Symptoms include fever, headache, dizziness, and transient exacerbation of lymphangitis. DEC induces the Mazzotti reaction when administered in the setting of onchocerciasis (eg, pruritus, ocular and constitutional symptoms). In areas of West Africa where loiasis is endemic, DEC should be used with caution; it should not be administered to individuals with high-grade microfilaremia who are susceptible to treatment-induced encephalopathy. (See
         <a class="medical medical_review" href="/z/d/html/5684.html" rel="external">
          "Loiasis (Loa loa infection)"
         </a>
         .)
        </p>
        <p>
         In the United States, DEC is available from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fncezid%2Fdsr%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLL5728He%2FvLdtW8%2FxFATkgal4zg3beQEfCZcaI9sLBQG&amp;TOPIC_ID=487" target="_blank">
          Centers for Disease Control and Prevention Drug Service
         </a>
         .
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Pyrantel
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pyrantel is a well-tolerated pyrimidine derivative that acts against intestinal nematodes by inducing neuromuscular paralysis, allowing worms to be expelled. A single dose is usually curative for ascariasis, enterobiasis, and trichostrongyliasis; several doses are recommended for hookworm infection. It is not active against
         <em>
          Trichuris trichiura
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">
          "Ascariasis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5692.html" rel="external">
          "Enterobiasis (pinworm) and trichuriasis (whipworm)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5694.html" rel="external">
          "Miscellaneous nematodes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5721.html" rel="external">
          "Hookworm infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Nitazoxanide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">
          Nitazoxanide
         </a>
         is a nitrothiazolyl-salicylamide derivative with an uncertain mechanism of action [
         <a href="#rid3">
          3
         </a>
         ]. Nitazoxanide has US Food and Drug Administration approval for treatment of two protozoan enteric infections, giardiasis and cryptosporidiosis. (See
         <a class="medical medical_review" href="/z/d/html/6024.html" rel="external">
          "Giardiasis: Treatment and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16217.html" rel="external">
          "Cryptosporidiosis: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
         There is limited clinical experience with
         <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">
          nitazoxanide
         </a>
         for treatment of intestinal helminths including
         <em>
          Ascaris
         </em>
         ,
         <em>
          Trichuris
         </em>
         ,
         <em>
          Enterobius
         </em>
         , as well as the dwarf tapeworm,
         <em>
          Hymenolepis nana
         </em>
         , and
         <em>
          Fasciola hepatica
         </em>
         [
         <a href="#rid1">
          1,3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21576467">
         <span class="h2">
          Oxamniquine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oxamniquine is a tetrahydroquinolone derivative that is used as an alternative agent for the treatment of
         <em>
          Schistosoma mansoni
         </em>
         [
         <a href="#rid1">
          1
         </a>
         ]. Higher doses are required in Egypt and South Africa for partially resistant strains; completely resistant strains have also been encountered. Oxamniquine is well tolerated, with occasional side effects of headache, dizziness, drowsiness, and gastrointestinal disturbances. Oxamniquine is contraindicated for use during pregnancy and is not available in the United States. (See
         <a class="medical medical_review" href="/z/d/html/5705.html" rel="external">
          "Schistosomiasis: Treatment and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21576510">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Helminths
         </strong>
         – Helminths are multicellular parasites with complex life cycles within and outside of human hosts. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ivermectin
         </strong>
         <strong>
         </strong>
         – (see
         <a class="local">
          'Ivermectin'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         is the drug of choice for the treatment of onchocerciasis and for strongyloidiasis. Ivermectin is effective against several intestinal nematodes including ascariasis, trichuriasis, and enterobiasis. Ivermectin is also effective for treatment of ectoparasitic infestations including scabies and head lice.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">
          Ivermectin
         </a>
         has activity against other filarial worms including
         <em>
          Wuchereria bancrofti
         </em>
         ,
         <em>
          Brugia malayi
         </em>
         , and
         <em>
          Loa loa
         </em>
         ; it is not the drug of choice for these infections, though it may be useful in certain circumstances.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benzimidazoles
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Albendazole
         </strong>
         –
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          Albendazole
         </a>
         has a broad range of activity against helminthic infections, including neurocysticercosis, echinococcosis, ascariasis, hookworm, and trichuriasis. Albendazole also has activity against a number of less common tissue nematode infections. (See
         <a class="local">
          'Albendazole'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mebendazole
         </strong>
         –
         <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">
          Mebendazole
         </a>
         is a benzimidazole derivative that is effective against a spectrum of intestinal and tissue nematode infections, including ascariasis, hookworm, enterobiasis, and trichuriasis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Triclabendazole
         </strong>
         –
         <a class="drug drug_general" data-topicid="120383" href="/z/d/drug information/120383.html" rel="external">
          Triclabendazole
         </a>
         is the drug of choice for treatment of liver fluke infections due to
         <em>
          Fasciola hepatica
         </em>
         . (See
         <a class="local">
          'Triclabendazole'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Praziquantel
         </strong>
         –
         <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">
          Praziquantel
         </a>
         has activity against schistosomiasis, intestinal tapeworms, cysticercosis, and other flukes (exclusive of
         <em>
          Fasciola hepatica
         </em>
         ). (See
         <a class="local">
          'Praziquantel'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diethylcarbamazine
         </strong>
         <strong>
          (DEC)
         </strong>
         – DEC has activity against lymphatic filariasis, loiasis, and visceral larva migrans. DEC induces the Mazzotti reaction when administered in the setting of onchocerciasis (eg, pruritus, ocular and constitutional symptoms). (See
         <a class="local">
          'Diethylcarbamazine'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.
         </li>
         <li class="breakAll">
          World Health Organizaton. Preventive chemotherapy in human helminthiasis: Coordinated use of anthelminthic drugs in control interventions: A manual for health professionals and programme managers. WHO, Geneva 2006. http://apps.who.int/iris/bitstream/10665/43545/1/9241547103_eng.pdf (Accessed on May 31, 2017).
         </li>
         <li class="breakAll">
          Leder K, McGuinness SL, Weller PF. Antiparasitic agents. In: Manual of Clinical Microbiology, 12, Jorgenson JH, Pfaller MA, Carroll KC, et al (Eds), American Society of Microbiology, Washington 2019. p.2645.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ojha SC, Jaide C, Jinawath N, et al. Geohelminths: public health significance. J Infect Dev Ctries 2014; 8:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor-Robinson DC, Maayan N, Soares-Weiser K, et al. Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance. Cochrane Database Syst Rev 2012; 11:CD000371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009; 373:1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox LM. Ivermectin: uses and impact 20 years on. Curr Opin Infect Dis 2006; 19:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulz JD, Coulibaly JT, Schindler C, et al. Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. J Antimicrob Chemother 2019; 74:1642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duthaler U, Suenderhauf C, Karlsson MO, et al. Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. Br J Clin Pharmacol 2019; 85:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz J, Ballester MR, Antonijoan RM, et al. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl Trop Dis 2018; 12:e0006020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989; 40:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990; 6:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies HD, Sakuls P, Keystone JS. Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol 1993; 129:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatia V, Sarin SK. Hepatic visceral larva migrans: evolution of the lesion, diagnosis, and role of high-dose albendazole therapy. Am J Gastroenterol 1994; 89:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraivichian P, Kulkumthorn M, Yingyourd P, et al. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg 1992; 86:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross JH, Basaca-Sevilla V. Albendazole in the treatment of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1987; 18:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu YH, Wang XG, Gao P, Qian MX. Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis. Chin Med J (Engl) 1991; 104:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oostburg BF. The sixth case of lagochilascariasis minor in Surinam. Trop Geogr Med 1992; 44:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews JR, Ainsworth R, Abernethy D. Trichinella pseudospiralis in humans: description of a case and its treatment. Trans R Soc Trop Med Hyg 1994; 88:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krepel HP, Haring T, Baeta S, Polderman AM. Treatment of mixed Oesophagostomum and hookworm infection: effect of albendazole, pyrantel pamoate, levamisole and thiabendazole. Trans R Soc Trop Med Hyg 1993; 87:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988; 34:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahmias J, Goldsmith R, Soibelman M, el-On J. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 1994; 88:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millán JC, Mull R, Freise S, et al. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 2000; 63:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lecaillon JB, Godbillon J, Campestrini J, et al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol 1998; 45:601.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Parasites. Fasciola. https://www.cdc.gov/parasites/fasciola/health_professionals/index.html (Accessed on March 05, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grove DI. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans R Soc Trop Med Hyg 1982; 76:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002; 185:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross HF, Haarbrink M, Egerton G, et al. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet 2001; 358:1873.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 487 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://apps.who.int/iris/bitstream/10665/43545/1/9241547103_eng.pdf" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : World Health Organizaton. Preventive chemotherapy in human helminthiasis: Coordinated use of anthelminthic drugs in control interventions: A manual for health professionals and programme managers. WHO, Geneva 2006. http://apps.who.int/iris/bitstream/10665/43545/1/9241547103_eng.pdf (Accessed on May 31, 2017).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Leder K, McGuinness SL, Weller PF. Antiparasitic agents. In: Manual of Clinical Microbiology, 12, Jorgenson JH, Pfaller MA, Carroll KC, et al (Eds), American Society of Microbiology, Washington 2019. p.2645.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24423707" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Geohelminths: public health significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23152203" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin and school performance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19410718" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Rescuing the bottom billion through control of neglected tropical diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17075336" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ivermectin: uses and impact 20 years on.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30859185" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30566757" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29346388" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2929853" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Ivermectin for human strongyloidiasis and other intestinal helminths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15463312" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mode of action of benzimidazoles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8481019" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8147371" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hepatic visceral larva migrans: evolution of the lesion, diagnosis, and role of high-dose albendazole therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1440822" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Albendazole for the treatment of human gnathostomiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3448777" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Albendazole in the treatment of intestinal capillariasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1879192" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1496709" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The sixth case of lagochilascariasis minor in Surinam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8036673" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Trichinella pseudospiralis in humans: description of a case and its treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8465409" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment of mixed Oesophagostomum and hookworm infection: effect of albendazole, pyrantel pamoate, levamisole and thiabendazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3396623" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Increased systemic availability of albendazole when taken with a fatty meal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7944675" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11421375" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11389487" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Imported Fasciola hepatica infection in the United States and treatment with triclabendazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9663817" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effect of food on the bioavailability of triclabendazole in patients with fascioliasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9663817" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effect of food on the bioavailability of triclabendazole in patients with fascioliasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7080143" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11920298" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11741630" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
